DBPR114 was initially developed as a dual FLT3/AURK multikinase inhibitor for the treatment of FLT3 internal tandem duplication alteration-positive acute myeloid leukemia (AML) tumors and FLT3 wild-type AML tumors. The gene discussed is FLT3; the disease is acute myeloid leukemia.